Select Language:
A new study indicates that combining immunotherapy with radiation treatment could prolong cancer-free periods for men with highly aggressive prostate cancer, offering renewed hope for patients facing one of the most difficult types of the disease to manage.
Research conducted by scientists at Moffitt Cancer Center and published in the Journal for ImmunoTherapy of Cancer highlights this potential breakthrough.
Prostate cancer impacts millions globally and is one of the most common cancers among older men. While many prostate tumors grow slowly and can be effectively managed over years, some behave very differently.
Grade Group 5 prostate cancer is recognized as one of the most aggressive forms. These tumors tend to grow rapidly, metastasize more frequently, and pose a higher risk of becoming life-threatening.
Due to this elevated risk, doctors often employ multiple treatments simultaneously to contain the disease before it spreads further.
In this latest research, investigators explored whether immunotherapy could enhance the effectiveness of radiation therapy.
Unlike chemotherapy or radiation, immunotherapy doesn’t attack cancer cells directly but instead boosts the body’s immune system, helping it identify and eliminate cancer more efficiently.
The drug used in the study was nivolumab, an immunotherapy already approved for treating various other cancers.
Cancer cells sometimes evade immune detection by turning off immune cells through proteins called checkpoints. Nivolumab blocks one of these checkpoints, keeping immune cells active against tumor cells.
Scientists hypothesized that combining radiation therapy with immunotherapy might produce synergistic effects. Radiation damages cancer cells and might release signals that make tumors more visible to the immune system. The goal was to administer nivolumab before and during radiation to amplify immune responses.
The study involved 31 men diagnosed with Grade Group 5 prostate cancer. Each participant underwent an intensive treatment regimen that included hormone therapy to lower growth-stimulating hormones and two types of radiation treatments:
– Brachytherapy: this involves placing radioactive material directly inside the prostate, allowing high doses to target the tumor precisely.
– External beam radiation: using external machines to direct radiation at the prostate.
Patients began nivolumab about a month before starting radiation and continued throughout their radiation therapy.
Monitoring involved routine PSA blood tests, which measure prostate cancer activity. Elevated PSA levels can indicate the cancer’s return or progression.
After two years, approximately 90% of the participants showed no biochemical signs of cancer recurrence. For patients with such high-risk disease, these results are encouraging.
Furthermore, the combination appeared to be well tolerated, with no severe toxic side effects reported despite the aggressive treatment approach.
An interesting aspect of the study was the use of a genetic biomarker called the Decipher immunosuppression score, which assesses how strongly the tumor interacts with the immune system. Patients with higher scores responded more favorably, suggesting that such biomarkers might help identify patients most likely to benefit from immunotherapy in future treatments.
Lead researcher Kosj Yamoah explained that initiating immune activation early—before radiation damages tumor cells—was a strategic approach, aiming to help the immune system recognize and attack remaining cancer cells more effectively.
While these findings are promising, they are still preliminary due to the small sample size and lack of a control group receiving only standard treatment. Longer follow-up is necessary to determine whether the positive effects continue over time, considering that prostate cancer can recur years after initial therapy.
The next step involves larger, randomized trials comparing the combined approach directly against standard treatments, with hopes of identifying which patients are most likely to benefit based on tumor characteristics or biomarkers.
Despite significant advances, aggressive prostate cancer remains a formidable challenge, as many patients experience recurrence despite intensive therapies. Combining immunotherapy with radiation is garnering increasing scientific interest because these treatments may reinforce each other’s effects, leading to better outcomes.
This research opens the door to more personalized prostate cancer treatments, leveraging immune biomarkers and combination therapies. Although further studies are essential before altering clinical guidelines, early results suggest that activating the immune system alongside radiation could become a vital strategy against high-risk prostate cancers.
For those interested in prostate cancer, exploring recent research on bacteria linked to aggressive forms and novel treatment strategies for advanced disease can provide valuable insights. Additional promising areas include new methods to reduce metastatic spread and treatments that combine multiple drugs to improve survival rates in advanced cases.
Source: Moffitt Cancer Center
ChatGPT
Perplexity
Gemini AI
Grok AI
